The purpose of this study is to learn about experiences of patients with hemophilia A and B after taking gene therapy. The experiences of patients will be studied through online interviews. This study is seeking participants who are: * part of the Pfizer's gene therapy clinical studies or * in the long-term follow up for these clinical programs. Participants will have one study visit at the clinic and one online interview. The planned duration for each participant will be 1 to 2 months. This covers the time from entering the study to end of the online interview.
Study Type
OBSERVATIONAL
Frequency of self-reported symptoms pre and post hemophilia gene therapy
Time frame: From date of dosing in the gene therapy clinical trial until the interview date, no less than 52 weeks.
Frequency of self-reported severity pre and post hemophilia gene therapy
Time frame: From date of dosing in the gene therapy clinical trial until the interview date, no less than 52 weeks.
Frequency of self-reported impacts pre and post hemophilia gene therapy
Time frame: From date of dosing in the gene therapy clinical trial until the interview date, no less than 52 weeks.
Change in the proportion of patients answering 5-point Likert scale questions about the burden of hemophilia on the participant's life pre-post gene therapy
Time frame: From date of dosing in the gene therapy clinical trial until the interview date, no less than 52 weeks.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.